CardioGenx (CGX) role will be to develop in vitro models and animal models that can be used in WP2 (Target validation – in vitro and in vivo models) to study the biological role as well as validate the drugability of the candidate genes in several stages of cardiovascular disease, (including atherosclerosis and myocardial infarction).
CardioGenX is a start-up company that spun off out of the Thoraxcenter of the Erasmus University Medical Centre Rotterdam and the Experimental Cardiology department of the University Medical Center (UMC) in Utrecht. The Thoraxcenter Rotterdam is one of the leading centres of excellence for cardiology and in particular Interventional Cardiology worldwide. The centre has played a central role in the initiation of various technologies that are currently regarded as point of care. Within the Thoraxcenter three specific units closely collaborate with Interventional Cardiology to initiate and perform new research projects: Experimental Cardiology; Biomedical Engineering, and Clinical Epidemiology. Current topics under investigation include stem cells technology, atherosclerosis and vulnerable plaque formation, drug eluting stents, and chronic total occlusions. The Experimental Cardiology department of the UMC has its main focus on basic science and therapy orientated research in cardiovascular disease. The group is enrolled in studies that assess the biological mechanisms underlying the process of atherosclerosis. Using murine and in vitro cell models that closely mimic human cardiovascular diseases, our group has identified and studied new molecular regulators in the onset and progression of atherosclerosis and myocardial infarction. Both institutes support a state of the art animal facility and core technologies that allow the performance of cutting edge research with both basic and translational scientific value. Moreover, we are running a clinical study to identify biomarkers for cardiac ischemia from circulating cell types.